Replies to post #17465 on Endonovo Therapeutics Inc (ENDV)

[sello]

Biotech stocks are a different animal. No revenue and accumulated debt are expected. The value is in the potential of what is being developed. There are many articles out there talking about the potential of this field and two companies are typically in the forefront, Endonovo Therapeutics and Pulse Biosciences. Pulse is a little further along in the process but they also have no revenues. A little over a month ago they were over a 500 million market cap. That equates to $2.00 a share if ENDV follows a similar path. The only thing Endonovo has to do at this point to begin moving in the same direction as PLSE is to release positive preclinical results and that could happen any day now. This is a potential monster in the making, and while it may look rough right now this is one that you definitely want to watch at the very least. IMO